About this study
This study will enroll participants who have melanoma or other solid tumors or lymphoma that is growing or has come back after receiving standard therapy. People with these conditions are usually treated with surgeries and/or chemotherapy using drugs approved by the U.S. Food and Drug Administration (FDA) because there is no standard therapy for this type of cancer. The drug in this study is called pembrolizumab.
Before enrolling, prospective participants will be screened. This process will include certain exams, tests, or procedures to make sure this study is a good option for them.
Purpose of this clinical trial
The main goal of the study is to see how safe and effective pembrolizumab is in treating children with these conditions. Researchers also want to learn the good and bad side effects of this medicine.
Eligibility overview
- Between 6 months and 18 years old with diagnosis of MSI-H solid tumor OR
- Between 3 and 18 years old with relapsed or refractory classical Hodgkin lymphoma OR
- Between 12 and 18 years old with diagnosis of melanoma OR
- Between 12 and 18 years old with a diagnosis of Stage IIB, IIC, III, or IV melanoma, who had prior surgery to remove the tumor, but no other treatment (including radiation), no metastatic disease, and who have completely recovered
- Negative pregnancy test 72 hours prior to medication administration in participants of child-bearing potential
- Appropriate liver and kidney functions